A Multicenter, 24-52-Week, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, and Safety of Saredutant 100 mg Once Daily in the Prevention of Relapse of Depressive Symptoms in Outpatients With Major Depressive Disorder.

Trial Profile

A Multicenter, 24-52-Week, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, and Safety of Saredutant 100 mg Once Daily in the Prevention of Relapse of Depressive Symptoms in Outpatients With Major Depressive Disorder.

Completed
Phase of Trial: Phase III

Latest Information Update: 25 May 2016

At a glance

  • Drugs Saredutant (Primary)
  • Indications Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Acronyms MAGENTA
  • Sponsors Sanofi
  • Most Recent Events

    • 28 Jul 2011 Actual end date (Apr 2008) added as reported by ClinicalTrials.gov.
    • 07 Jul 2009 Actual end date (Apr 2008) added as reported by ClinicalTrials.gov.
    • 07 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top